Posted by Michael Wonder on 12 Oct 2022
Thousands of Kiwi with severe asthma given access to newly funded medicine
10 October 2022 - Thousands of Kiwis at higher risk of death from a severe form of respiratory disease will be able to access a newly funded medicine for the disease.
A New Zealand Government funding boost for the treatment of severe eosinophilic asthma in patients 12 years and over will provide funded access to a medicine called Fasenra (benralizumab), which is designed to target and remove eosinophils, a key cause of severe asthma.
